(Q34977381)

English

A phase I/II trial of the histone deacetylase inhibitor romidepsin for adults with recurrent malignant glioma: North American Brain Tumor Consortium Study 03-03.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

A phase I/II trial of the histone deacetylase inhibitor romidepsin for adults with recurrent malignant glioma: North American Brain Tumor Consortium Study 03-03. (English)

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

phase I clinical trial

0 references

phase II clinical trial

0 references

1 reference

based on heuristic

inferred from title

4

object named as

Patrick Y Wen

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

author name string

Fabio M Iwamoto

1

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Kathleen R Lamborn

2

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

John G Kuhn

3

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

W K Alfred Yung

5

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Mark R Gilbert

6

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Susan M Chang

7

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Frank S Lieberman

8

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Michael D Prados

9

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Howard A Fine

10

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

publication date

3 March 2011

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

13

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

509-516

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3093337

8 July 2018

Joint NCCTG and NABTC prognostic factors analysis for high-grade recurrent glioma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3093337

8 July 2018

Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3093337

8 July 2018

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3093337

8 July 2018

Lysine acetylation targets protein complexes and co-regulates major cellular functions

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3093337

8 July 2018

DNER, an epigenetically modulated gene, regulates glioblastoma-derived neurosphere cell differentiation and tumor propagation.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3093337

8 July 2018

Population pharmacokinetics of romidepsin in patients with cutaneous T-cell lymphoma and relapsed peripheral T-cell lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3093337

8 July 2018

Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3093337

8 July 2018

Malignant gliomas in adults

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3093337

8 July 2018

Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3093337

8 July 2018

Tolerability, pharmacodynamics, and pharmacokinetics studies of depsipeptide (romidepsin) in patients with acute myelogenous leukemia or advanced myelodysplastic syndromes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3093337

8 July 2018

Anticancer activities of histone deacetylase inhibitors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3093337

8 July 2018

Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3093337

8 July 2018

A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3093337

8 July 2018

Histone deacetylase inhibitor, FK228, induces apoptosis and suppresses cell proliferation of human glioblastoma cells in vitro and in vivo

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3093337

8 July 2018

Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3093337

8 July 2018

Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3093337

8 July 2018

Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3093337

8 July 2018

Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOR017

21 January 2018

Identification of cytochrome P450 enzymes involved in the metabolism of FK228, a potent histone deacetylase inhibitor, in human liver microsomes

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOR017

21 January 2018

Response criteria for phase II studies of supratentorial malignant glioma

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOR017

21 January 2018

Plasma and cerebrospinal fluid pharmacokinetics of depsipeptide (FR901228) in nonhuman primates

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOR017

21 January 2018

Expression of drug resistance proteins Pgp, MRP1, MRP3, MRP5 and GST-pi in human glioma.

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOR017

21 January 2018

FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3093337

26 October 2018

Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228

1 reference

https://pubmed.ncbi.nlm.nih.gov/21377994

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Inhibition and induction of cytochrome P450 and the clinical implications

1 reference

https://pubmed.ncbi.nlm.nih.gov/21377994

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Determination of the antitumor agent depsipeptide in plasma by liquid chromatography on serial octadecyl stationary phases

1 reference

https://pubmed.ncbi.nlm.nih.gov/21377994

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cardiotoxicity of histone deacetylase inhibitor depsipeptide in patients with metastatic neuroendocrine tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/21377994

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I study of depsipeptide in pediatric patients with refractory solid tumors: a Children's Oncology Group report

1 reference

https://pubmed.ncbi.nlm.nih.gov/21377994

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1093/NEUONC/NOR017

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34977381&oldid=1749484565"